ストックスクリーナーアプリを入手
31.73
35.24%
-17.27
アフターアワーズ：
32.20
0.47
+1.48%
Maze Therapeutics Inc (MAZE) 最新ニュース
Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease - Yahoo Finance
Maze Therapeutics' (MAZE) "Buy" Rating Reiterated at BTIG Research - MarketBeat
BTIG reiterates Maze Therapeutics stock rating on trial results By Investing.com - Investing.com Canada
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Maze Therapeutics (NASDAQ:MAZE) Shares Gap DownTime to Sell? - MarketBeat
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data By Investing.com - Investing.com Australia
Truist reiterates Buy on Maze Therapeutics stock after trial data By Investing.com - Investing.com Canada
Maze Therapeutics posts trial data for lead drug (MAZE:NASDAQ) - Seeking Alpha
HC Wainwright Raises Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00 - MarketBeat
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data - Investing.com
Leerink reiterates Maze Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Why Maze Therapeutics Stock Is Sinking After Good News - TipRanks
Maze Therapeutics stock soars 22% on positive trial data for MZE829 - Investing.com
Maze Therapeutics adds Neil Kumar to board leadership - TipRanks
Earnings Flash (MAZE) Maze Therapeutics Posts Q4 Net Loss $0.65 a Share, vs. FactSet Est of $0.72 Loss - marketscreener.com
Maze Therapeutics 2025 10-K: Revenue $0M, EPS $(3.05) - TradingView
Maze appoints Neil Kumar to its board as Class I director - TradingView
Maze Therapeutics Inc. unveils encouraging results for MZE829 APOL1 inhibitor in AMKD patients - Traders Union
Maze Therapeutics reports bigger-than-expected Q4 loss on higher R&D costs - TradingView
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease - The Manila Times
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights - Bluefield Daily Telegraph
Portfolio Shifts: What analysts say about Maze Therapeutics Inc stockFed Meeting & AI Driven Price Forecasts - baoquankhu1.vn
This Evommune analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
This strategy analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday - MSN
Maze Therapeutics (MAZE) Executive Stock Sale & 2026 Company PerformanceNews and Statistics - IndexBox
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears - Yahoo Finance
Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears - The Motley Fool
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Maze Therapeutics president Bernstein sells $736k in stock By Investing.com - Investing.com Canada
Maze Therapeutics (NASDAQ:MAZE) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat
Truist Securities initiates coverage of Maze Therapeutics (MAZE) with buy recommendation - MSN
Fundamentals Check: What analysts say about Maze Therapeutics Inc stockEarnings Growth Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
Wells Fargo initiates coverage of Maze Therapeutics (MAZE) with overweight recommendation - MSN
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Truist initiates Maze Therapeutics stock coverage with buy rating By Investing.com - Investing.com Canada
Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade - Defense World
Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Foresite Capital Management IV LLC Sells 1,589,262 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Foresite Capital Management V LLC Sells 258,900 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. News — NASDAQ:MAZE - TradingView
Boothbay Fund Management LLC Acquires 276,345 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
545,132 Shares in Maze Therapeutics, Inc. $MAZE Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
Maze Therapeutics stock hits all-time high at 49.28 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Mizuho - Defense World
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at Mizuho - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 30,000 Shares - MarketBeat
Maze Therapeutics Executive Sells All Common Stock Holdings - TradingView
Maze Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Maze Therapeutics stock hits all-time high at 49.28 USD - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Mizuho initiates coverage of Maze Therapeutics (MAZE) with outperform recommendation - MSN
Maze Therapeutics (NASDAQ:MAZE) Shares Up 8.5%Here's Why - MarketBeat
Why Maze Therapeutics Stock Is Suddenly Surging - TipRanks
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Mizuho Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Mizuho initiates Maze Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Maze Therapeutics’ (MAZE) “Buy” Rating Reaffirmed at BTIG Research - Defense World
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE - TipRanks
1.82%
大文字化:
|
ボリューム (24 時間):